Normal antibody response after COVID-19 during treatment with cladribine.
Mult Scler Relat Disord
; 46: 102476, 2020 Nov.
Article
in English
| MEDLINE | ID: covidwho-733681
ABSTRACT
Cladribine is a highly effective, recently available treatment in multiple sclerosis. This case report describes a patient with COVID-19 infection during second year treatment with cladribine. The infection was mild and she was able to mount an adequate immune response with detectable antibodies three months later.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Cladribine
/
SARS-CoV-2
/
COVID-19 Drug Treatment
/
Antibodies, Viral
/
Antibody Formation
Topics:
Long Covid
Limits:
Female
/
Humans
Language:
English
Journal:
Mult Scler Relat Disord
Year:
2020
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS